X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (874) 874
Publication (105) 105
Newsletter (45) 45
Book Review (12) 12
Book Chapter (11) 11
Book / eBook (3) 3
Journal / eJournal (3) 3
Conference Proceeding (2) 2
Web Resource (2) 2
Data Set (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
kala-azar (693) 693
humans (591) 591
visceral leishmaniasis (497) 497
index medicus (456) 456
animals (369) 369
parasitic diseases (353) 353
leishmaniasis (329) 329
female (276) 276
male (275) 275
parasitology (248) 248
azar dermal leishmaniasis (228) 228
infectious diseases (223) 223
tropical medicine (219) 219
immunology (213) 213
adult (211) 211
diagnosis (202) 202
research (189) 189
leishmaniasis, visceral - epidemiology (187) 187
cutaneous leishmaniasis (170) 170
leishmaniasis, visceral - drug therapy (160) 160
adolescent (156) 156
child (147) 147
antiprotozoal agents - therapeutic use (145) 145
leishmaniasis, visceral - diagnosis (145) 145
leishmaniasis, visceral - immunology (134) 134
health aspects (132) 132
leishmaniasis, visceral - parasitology (132) 132
middle aged (129) 129
india (126) 126
microbiology (124) 124
parasites (123) 123
epidemiology (119) 119
tropical diseases (117) 117
leishmania donovani (114) 114
research article (114) 114
care and treatment (113) 113
infection (113) 113
leishmania (109) 109
infections (106) 106
public, environmental & occupational health (105) 105
child, preschool (101) 101
medicine (100) 100
analysis (95) 95
donovani (91) 91
arctic medicine. tropical medicine (90) 90
sudan (90) 90
young adult (90) 90
public aspects of medicine (82) 82
risk factors (82) 82
vector-borne diseases (81) 81
medical research (79) 79
sodium stibogluconate (79) 79
liposomal amphotericin-b (78) 78
leishmania donovani - isolation & purification (76) 76
leishmaniasis, visceral - prevention & control (76) 76
mice (75) 75
miltefosine (75) 75
india - epidemiology (74) 74
leishmania donovani - immunology (72) 72
post-kala-azar dermal leishmaniasis (72) 72
drug resistance (71) 71
leishmaniasis, visceral - complications (71) 71
public health (71) 71
medicine and health sciences (67) 67
direct agglutination-test (66) 66
antibodies, protozoan - blood (63) 63
dogs (63) 63
polymerase chain reaction (60) 60
medicine, experimental (59) 59
biology and life sciences (58) 58
human-immunodeficiency-virus (58) 58
neglected tropical diseases (58) 58
antigens (56) 56
drug therapy (56) 56
interferon-gamma (56) 56
sensitivity and specificity (56) 56
leishmaniasis, visceral - pathology (55) 55
immune response (54) 54
leishmaniasis, cutaneous - diagnosis (54) 54
review (54) 54
zoonoses (54) 54
infant (52) 52
usage (52) 52
dermatology (51) 51
indian kala-azar (51) 51
pharmacology & pharmacy (51) 51
bangladesh (50) 50
leishmania donovani - genetics (50) 50
leishmaniasis, cutaneous - drug therapy (50) 50
leishmaniasis, cutaneous - parasitology (50) 50
vaccines (50) 50
bihar (49) 49
leishmaniasis, visceral - transmission (49) 49
treatment outcome (49) 49
aged (48) 48
antigens, protozoan - immunology (48) 48
disease transmission (48) 48
donovani infection (47) 47
hiv (47) 47
medicine, general & internal (47) 47
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Post-kala-azar dermal leishmaniasis: a histopathological study, 12/2005
BACKGROUND : Post-kala-azar dermal leishmaniasis follows an attack of visceral leishmaniasis and is caused by the same organism, i.e. Leishmania donovani .... 
Post kala-azar dermal leishmaniasis, Hypopigmented macules, Nodules, Plaques, Histopathology
Journal
Mucosal and peri-orificial involvement in post-kala-azar dermal leishmaniasis, 09/2004
BACKGROUND AND AIMS: Lesions of post-kala-azar dermal leishmaniasis (PKDL) usually affect the skin. Uncommonly, the involvement of oral and genital mucosae has... 
Dermatology | Post-kala-azar dermal leishmaniasis, oral mucosa, genital lesions, peri-orificial lesions dv04096
Journal
Cornea, ISSN 0277-3740, 01/2018, Volume 37, Issue 1, pp. 113 - 115
PURPOSE:To report 2 cases of keratitis occurring after post-kala-azar dermal leishmaniasis (PKDL) in immunocompetent patients. METHODS:Case report and... 
Keratitis | Treatment | PKDL | Dermal | Kala azar | Leishmaniasis | Immunocompetent | keratitis | treatment | OPHTHALMOLOGY | immunocompetent | kala azar | leishmaniasis | dermal
Journal Article
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, ISSN 2235-2988, 07/2019, Volume 9, p. 228
Post-kala-azar dermal leishmaniasis (PKDL) follows visceral leishmaniasis (VL, kala-azar) in 10-60% of cases. It is characterized by an asymptomatic skin rash,... 
parasitological | IMMUNE-RESPONSE | DIAGNOSIS | biochemical | DONOVANI | biomarkers | post-kala-azar dermal leishmaniasis | PKDL | MICROBIOLOGY | IMMUNOLOGY | FEATURES | clinical | SUDAN | MILTEFOSINE | IMMUNOLOGICAL DETERMINANTS | VISCERAL LEISHMANIASIS | PCR ASSAY | immunological | Leishmaniasis | Research | Biological markers | Analysis | Cytology | Diagnosis
Journal Article
Therapeutic trial of sodium antimony gluconate alone and in combination with ketoconazole in post-kala-azar dermal leishmaniasis (PKDL), 11/2003
Drugs used in PKDL include parenteral sodium antimony gluconate (SAG), amphotericin-B, pentamidine, and ketoconazole (KTZ). SAG is the most effective one.... 
Dermatology | Post-kala-azar dermal leishmaniasis, Sodium antimony gluconate, Ketoconazole dv03073
Journal
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 07/2019, Volume 69, Issue 2, pp. 251 - 258
Background. On the Indian subcontinent, visceral leishmaniasis (VL) incidence is on track to reach elimination goals by 2020 in nearly all endemic districts.... 
INFECTIOUS DISEASES | transmission | xenodiagnosis | post-kala-azar dermal leishmaniasis | ELIMINATION | INFANTUM | MICROBIOLOGY | IMMUNOLOGY | OUTBREAK | visceral leishmaniasis | and Commentaries
Journal Article
Trends in Parasitology, ISSN 1471-4922, 08/2019, Volume 35, Issue 8, pp. 590 - 592
Post-kala-azar dermal leishmaniasis (PKDL) is a parasitic skin infection which can occur after visceral leishmaniasis (VL). Recent xenodiagnosis studies... 
xenodiagnosis | post-kala-azar dermal leishmaniasis (PKDL) | visceral leishmaniasis | elimination | transmission dynamics | ELIMINATION | PARASITOLOGY | Kala-azar | Reservoirs | Disease transmission | Epidemiology | Analysis
Journal Article
PLoS Neglected Tropical Diseases, ISSN 1935-2727, 05/2017, Volume 11, Issue 5, p. e0005527
Background Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala... 
CUTANEOUS LEISHMANIASIS | IMMUNOGENICITY | CLINICAL-TRIAL | PROTECTION | LEISH-F1+MPL-SE VACCINE | EBOLA VACCINE | THERAPEUTIC VACCINATION | DONOVANI INFECTION | ADENOVIRUS | CD8(+) T-CELLS | PARASITOLOGY | TROPICAL MEDICINE | Antigens, Protozoan - immunology | Leishmaniasis Vaccines - immunology | Leishmaniasis, Visceral - prevention & control | Leishmaniasis Vaccines - adverse effects | Humans | Middle Aged | Male | Vaccines, Synthetic - immunology | Healthy Volunteers | Leishmaniasis, Cutaneous - prevention & control | Drug Carriers | Vaccines, Synthetic - isolation & purification | Adenoviruses, Simian - genetics | Young Adult | Leishmaniasis, Visceral - therapy | Flow Cytometry | Vaccines, Synthetic - adverse effects | Leishmaniasis, Cutaneous - therapy | Adult | Female | Antigens, Protozoan - genetics | Leishmaniasis Vaccines - isolation & purification | Interferon-gamma - secretion | Enzyme-Linked Immunospot Assay | Leishmaniasis Vaccines - administration & dosage | Injections, Intramuscular | Leishmania - immunology | Adolescent | Vaccines, Synthetic - administration & dosage | CD8-Positive T-Lymphocytes - immunology | Leishmania - genetics | Kala-azar | Care and treatment | Leishmaniasis | Research | Vaccines | Profiling | CD8 antigen | Metastasis | Immunity | Blood | Tropical diseases | Proteins | Parasitic diseases | Visceral leishmaniasis | Drug dosages | Antigens | T cell receptors | Nucleic acids | Gene expression | Disease control | Patients | Immunogenicity | Replication | Skin | Gene therapy | Health care | Drugs | Health sciences | Flow cytometry | Methodology | Vaccination | Clinical isolates | Clinical trials | Lymphocytes T | Identification | Biology | Infections | Medical schools | Immunosuppressive agents | Lymphocytes | Combined vaccines | Safety | Enzyme-linked immunosorbent assay | Vector-borne diseases | Immune response | Effectiveness | Ribonucleic acid--RNA | Flow | Cytometry | Respiratory syncytial virus | Adenoviruses | Fatalities | Interferon | RNA | Ribonucleic acid
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 01/2018, Volume 66, Issue 3, pp. 404 - 410
Background. The potential reservoirs of leishmaniasis in South Asia include relapsed cases of visceral leishmaniasis (VL), patients with post-Sala-azar dermal... 
ITS1-PCR | liposomal amphotericin B | miltefosine | parasite load | post-kala-azar dermal leishmaniasis | DIAGNOSIS | INFECTIOUS DISEASES | RK39 STRIP TEST | ORAL MILTEFOSINE | SERIES | ELIMINATION | MICROBIOLOGY | IMMUNOLOGY | VISCERAL LEISHMANIASIS
Journal Article
FRONTIERS IN MICROBIOLOGY, ISSN 1664-302X, 10/2019, Volume 10
Introduction: To sustain the achievement of kala-azar elimination program (KEP), early detection and treatment of the visceral leishmaniasis (VL) cases and... 
DIAGNOSIS | treatment failure (TF) | PROGNOSIS | rK39 antibody | relapse VL (RVL) | MICROBIOLOGY | BANGLADESH | RECOMBINANT K-39 | Post-kala-azar dermal leishmaniasis (PKDL) | ELIMINATION PROGRAM | visceral leishmaniasis (VL) | predictive biomarker | INDIA | ELISA | ANTIGEN
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2018, Volume 13, Issue 9, p. e0203407
Journal Article
International Journal of Infectious Diseases, ISSN 1201-9712, 04/2019, Volume 81, pp. 221 - 224
Post-kala-azar dermal leishmaniasis (PKDL) is a neglected tropical disease characterized by a dermatosis which often appears after successful treatment of... 
Miltefosine | Treatment | HIV | Ethiopia | East-Africa | Post-kala-azar dermal leishmaniasis | INFECTIOUS DISEASES | Medicine, Experimental | Medical research | HIV patients | Care and treatment | Leishmaniasis | HIV (Viruses)
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 08/2018, Volume 67, Issue 5, pp. 667 - 675
Abstract Background A safe and effective short-course treatment regimen for post-kala-azar dermal leishmaniasis (PKDL) is considered essential for achieving... 
liposomal amphotericin B | Bangladesh | Indian subcontinent | visceral leishmaniasis | AmBisome | post-kala-azar dermal leishmaniasis | INFECTIOUS DISEASES | MILTEFOSINE | MICROBIOLOGY | IMMUNOLOGY | INDIA
Journal Article